Table 8 Base case results for patients without cirrhosis
From: Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US
Genotype | Treatment | Duration (weeks) | Cost ($) | Effectiveness (QALYs) | ICER compared to benchmark ($/QALY) | Adjacent ICER ($/QALY) |
|---|---|---|---|---|---|---|
1 | Viekira Pak + Ribavirin | 12 | 97,380 | 19.9659 | dominant |  |
Harvoni | 12 | 106,830 | 19.9618 | dominant | dominated | |
Telaprevir + Peginterferon + Ribavirin for first 12 weeks, followed by additional 12 or 36 weeks of Peginterferon + Ribavirin | 12 + 12 or 36 | 108,820 | 18.3364 | benchmark | dominated | |
Sofosbuvir + Peginterferon + Ribavirin (Treatment-naïve) | 12 | 111,790 | 19.568 | 2,412 | dominated | |
Olysio + Sovaldi | 12 | 165,220 | 19.9356 | 35,268 | dominated | |
2 | Peginterferon + Ribavirin (Treatment-naïve) | 24 | 45,560 | 18.7853 | benchmark |  |
Initial: Peginterferon + Ribavirin; Follow-up: Sofosbuvir + Ribavirin for non-responders and relapsers. | 24 + 12 | 50,340 | 19.9145 | 4,233 | 4,233 | |
24 + 16 | 54,030 | 19.9975 | 6,987 | 44,457 | ||
Sofosbuvir + Ribavirin (Treatment-naïve) | 12 | 99,540 | 20.0227 | 43,624 | 1,805,952 | |
3 | Peginterferon + Ribavirin (Treatment-naïve) | 24 | 52,810 | 18.2828 | benchmark |  |
Initial: Peginterferon + Ribavirin; Follow-up: Sofosbuvir + Ribavirin for non-responders and relapsers. | 24 + 12 | 69,390 | 18.9351 | 25,418 | 25,418 | |
24 + 16 | 70,220 | 19.4892 | 14,431 | 1,498 | ||
Sofosbuvir + Ribavirin (Treatment-naïve) | 24 | 187,880 | 19.8033 | 88,833 | 374,594 |